Loading research and source information…
Parkinson’s disease · Drug research
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Evidence 1Content updated Oct 27, 2026 · Sources last checked Oct 27, 2026
Inclusion Criteria: * Body weight within 40-110 kilograms (kg) (88-242 pounds \[lbs\]) and a body mass index within the range 18-34 kg/m2 * Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria * Has received monotherapy treatment * An MDS-UPDRS Part IV score of 0 at screening and prior to randomization * Hoehn and Yahr (H\&Y) Stage 1 or 2 off medication at screening and prior to randomization * Agreement to adhere to the contraception requirements Exclusion Criteria: * Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required * Medical history indicating a parkinsonian syndrome other than idiopathic PD * Diagnosis of a significant neurologic disease other than PD * Chronic uncontrolled hypertension
This record covers only the linked trial population. This registry-based page does not review FDA approval or labeling.
FDA approval not reviewed here
Parkinson’s disease
See FDA labeling for the approved population and indication; this page covers the trial population only.
FDA labeling has not been reviewed for this page. This does not mean the treatment is unapproved.
Approval is specific to the indication and population. It does not establish availability, reimbursement or suitability for an individual.
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted resultsStudy ages: 50 Years to 85 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Australia, Austria, Brazil, Canada, China, Denmark, France, Germany, Italy, Mexico, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom, United States.
Sites marked recruiting: Australia, Austria, Brazil, Canada, China, Denmark, France, Germany, Italy, Mexico, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom, United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Jun 30, 2029 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1registry · Registry metadata is submitted by the sponsor or responsible party and does not independently validate efficacy.
No posted registry results are indicated in this source response. This does not establish that no results exist elsewhere.
Limitations: Outcomes, effect estimates, uncertainty and study quality have not been appraised. Consult original results and publications.
Evidence 1A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
registry · NCT07174310 · Structured source fields
Source date: Oct 6, 2026 · Checked: Oct 27, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: RECRUITING. Phase: PHASE3. Conditions: Parkinson's Disease.
Open original source